# Ticagrelor With Low-dose Versus Regular Aspirin in Patients With Acute Coronary Syndrome (ACS) at High-Risk for Ischemia After Percutaneous Coronary Intervention

Study · id `cardio:ct-nct04240834` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04240834](<https://clinicaltrials.gov/study/NCT04240834>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT04240834

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1220 participants.

## Technical summary

Registry record NCT04240834. Randomized; single masking; primary purpose treatment. Start 2021-02-01 (actual); primary completion 2025-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 1220 participants (planned count; ClinicalTrials.gov record NCT04240834, source copy `cardio:ctgov-nct04240834-2024-06-18`, retrieved 2026-10-31)
- Started: 2021-02-01 (actual) (ClinicalTrials.gov record NCT04240834, source copy `cardio:ctgov-nct04240834-2024-06-18`, retrieved 2026-10-31)
- Primary completion: 2025-12 (anticipated) (ClinicalTrials.gov record NCT04240834, source copy `cardio:ctgov-nct04240834-2024-06-18`, retrieved 2026-10-31)
- Completion: 2026-12 (anticipated) (ClinicalTrials.gov record NCT04240834, source copy `cardio:ctgov-nct04240834-2024-06-18`, retrieved 2026-10-31)
- Countries: China (ClinicalTrials.gov record NCT04240834, source copy `cardio:ctgov-nct04240834-2024-06-18`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04240834-2024-06-18`, retrieved 2026-10-31)

## The registry's words

- Brief title: Ticagrelor With Low-dose Versus Regular Aspirin in Patients With Acute Coronary Syndrome (ACS) at High-Risk for Ischemia After Percutaneous Coronary Intervention
- Acronym: LD-ASPIRIN
- Condition: Acute Coronary Syndrome
- Condition: Interventional Cardiology
- Intervention (Drug): Aspirin
- Intervention (Drug): Ticagrelor
- Lead sponsor: Fu Wai Hospital, Beijing, China
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Acute coronary syndrome (`cardio:acute-coronary-syndrome`)
- Registry intervention name matches this record: Aspirin (`core:aspirin`)
- Registry intervention name matches this record: Ticagrelor (`cardio:ticagrelor`)
- Registry lists this organization as the lead sponsor: Fu Wai Hospital, Beijing, China (`cardio:org-fu-wai-hospital-beijing-china`)

## Provenance

Content hash: 0d2b802a785c31bcb1b6ffa10f5289439a8a4b406a6e732bcf234513f0b3a8df
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
